Floatz logo

Epirubicin

Inflammatory Breast Carcinoma

Northwestern UniversityUNKNOWNPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Inflammatory Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Northwestern University
Phase 3BBB
Trastuzumab
Hoffmann-La Roche
Phase 3BBB
Carboplatin
Northwestern University
Phase 3BBB
Pertuzumab
Hoffmann-La Roche
Phase 3BBB
Docetaxel
Association Tunisienne de lutte Contre le Cancer
Phase 3BBB

View all 49 →

Same molecule, other indications

Epirubicin is also rated in:

estrogen-receptor negative breast cancerActive
BB
Indicative · Phase 2
71 / 100
View asset →
progesterone-receptor negative breast cancerActive
BB
Indicative · Phase 2
71 / 100
View asset →
hepatocellular carcinomaActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →